Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

40.19 -0.17 (-0.42%)
Streaming Delayed Price Updated: 12:02 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
41 42 Next >
Verona Pharma's Promising COPD Treatment Puts It in GSK's Acquisition Crosshairs, Analysts Predict Big Moves
In recent statements to the Financial Times and The Sunday Times, GSK plc (NYSE: GSK) Chief Commercial Officer Luke Miels revealed the company's intent to pursue acquisitions within the $2 billion... 
Via Benzinga
Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January
Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on... 
Via Benzinga
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations. 
Via Benzinga
3 Growth at a Reasonable Price (GARP) Stocks for Balanced Growth
GARP stocks are less likely to plunge than growth stocks with high valuations and more likely to generate strong growth than value stocks. 
Via InvestorPlace
GSK's Jemperli Cancer Drug Hits Primary Goal In Endometrial Cancer Study
GSK plc (NYSE: GSK)  
Via Benzinga
Looking Into GSK's Recent Short Interest
 
Via Benzinga
Price Over Earnings Overview: GSK
 
Via Benzinga
Merck's Chronic Cough Treatment Candidate Receives Second Time FDA Rejection
The FDA issued a Complete Response Letter (CRL) regarding Merck & Co Inc's (NYSE: MRK) New Drug Application (NDA) for gefapixant under development for the treatment of refractory chronic cough (RCC) or... 
Via Benzinga
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n 
Via Benzinga
GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity
From GSK plc
Via Business Wire
3 cheap 'stock'-ing stuffers Wall Street is bullish on
These three companies have Wall Street feeling bullish and are trading under $10, making them ideal ‘stock'-ing stuffers for hard to shop for traders. 
Via MarketBeat
Topics Stocks
Looking Into GSK's Recent Short Interest
 
Via Benzinga
Why Is Genetic Medicines-Focused Wave Life Sciences Stock Trading Lower Today?
Wave Life Sciences Ltd (NASDAQ: WVE) has priced its previously announced underwritten public offering of 20 million shares at $5.00 per share with approximately  
Via Benzinga
These biotechs targeting multiple neurodegenerative diseases
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market. 
Via MarketBeat
Competition and Optimism: GSK's CEO Walmsley Foresees Growth Despite Competition In RSV Vaccine Market
Emma Walmsley, the Chief Executive Officer of GSK plc (NYSE: GSK), expressed confidence in its respiratory syncytial virus (RSV) vaccine, Arexvy, anticipating sales to surpass £1 billio 
Via Benzinga
3 Stocks to Sell for Tax Losses Before the New Year
While no one wants to lose in the market, you can be productive with the red ink through stocks to sell for tax losses. 
Via InvestorPlace
3 Great Foreign Companies to Invest in Right Now
The world is a big place, and many great companies are based outside our U.S. borders. 
Via The Motley Fool
GSK Frames A Comeback For Its Multiple Myeloma Drug Following Encouraging Phase 3 Data
GSK plc (NYSE: GSK) announced headline  
Via Benzinga
Merck's Latest Drug For Chronic Cough Faces FDA Pushback
A panel of advisors to the Food and Drug Administration (FDA) reportedly expressed concerns about the efficacy of Merck & Company, Inc.'s (NYSE: 
Via Benzinga
Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion
Sen. Tommy Tuberville bought 3 tranches of put options to sell Tesla shares at $190 a day ahead of Q3 results that set in motion a stock slump. 
Via Benzinga
Diversifying Your Portfolio With Plant-Based Options
Investors see profit potential in the plant-based market due to rising consumer demand, ESG focus, and the growth of vegan products in various industries, including pharmaceuticals. However, market... 
Via Talk Markets
Major Buyout Firms Eye Sanofi's Consumer Health Division Spinoff Valued Over $20B
Sanofi SA (NYSE: SNY) has reportedly initiated talks with Rothschild & Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at over... 
Via Benzinga
Current Analysis: GSK Plc
In the pharmaceutical industry, GSK PLC ranks as one of the largest companies by total sales. 
Via Talk Markets
Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology
Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CVAC), accusing it of failing to credit Acuitas on patents related to... 
Via Benzinga
Topics Intellectual Property Lawsuit
European Drug Regulator Recommends Approval Of GSK's Bone Marrow Cancer Med
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a posi 
Via Benzinga
GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative
From GSK plc
Via Business Wire
6 Nasdaq 100 Stocks Down 40% or More that Will Soar As Much 367%
Wall Street is forever optimistic about the future for stocks and pegs these seven Nasdaq 100 stocks as ready for supersonic growth 
Via InvestorPlace
GSK is a remedy for the winter investment blahs
Pharma stock GSK is a remedy for the winter blahs with a low beta, a high yield, and value for investors. Sales of new drug Arexvy underpin results. 
Via MarketBeat
Topics Intellectual Property
3 Healthcare Stocks Getting Help From the Aging Population
America's aging population needs chronic conditions treatments, and these healthcare stocks are growing in the quest for healing solutions. 
Via InvestorPlace
3 Top Dividend Stock Picks for Steady Income and Capital Appreciation
Conservative investors will benefit from these top dividend stock picks that are likely to generate significant returns. 
Via InvestorPlace
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.